Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits - Wikidata - awgldk - TriplyDB

Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits

Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits

http://www.wikidata.org/entity/Q34543457

about

Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: insights from MRI/PET imaging Phosphodiesterases and cardiac cGMP: evolving roles and controversies Nitric oxide treatments as adjuncts to reperfusion in acute myocardial infarction: a systematic review of experimental and clinical studies Effects of sildenafil and/or muscle derived stem cells on myocardial infarction.Berbamine postconditioning protects the heart from ischemia/reperfusion injury through modulation of autophagy Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury.Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.Cardioprotective PKG-independent NO signaling at reperfusion Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice Adenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse.Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling.Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG Infarct limitation by a protein kinase G activator at reperfusion in rabbit hearts is dependent on sensitizing the heart to A2b agonists by protein kinase C Activation of the homeostatic intracellular repair response during cardiac surgery Sildenafil augments early protective transcriptional changes after ischemia in mouse myocardium Adverse impact of diet-induced hypercholesterolemia on cardiovascular tissue homeostasis in a rabbit model: time-dependent changes in cardiac parameters Regulation and pharmacology of the mitochondrial permeability transition pore.Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.Mitigation of indomethacin-induced gastric mucosal lesions by a potent specific type V phosphodiesterase inhibitor.Phosphodiesterase 5 inhibitors: are they cardioprotective?Erectile dysfunction as a cardiovascular risk factor in patients with diabetes.Novel approaches and opportunities for cardioprotective signaling through 3',5'-cyclic guanosine monophosphate manipulation.The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism.Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.Modulation of the ASK1-MKK3/6-p38/MAPK signalling pathway mediates sildenafil protection against chemical hypoxia caused by malonate.Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy.Comparative effects of verapamil, nicardipine, and nitroglycerin on myocardial ischemia/reperfusion injury.The role of cGMP-dependent protein kinase in controlling cardiomyocyte cGMP.Endothelial dysfunction in the human umbilical artery due to preeclampsia can be prevented by sildenafil.Pharmacological postconditioning by bolus injection of phosphodiesterase-5 inhibitors vardenafil and sildenafil.Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice.Tadalafil prevents acute heart failure with reduced ejection fraction in mice.BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts.Ovariectomy reinstates the infarct size-limiting effect of postconditioning in female rabbits.

P2860

Q27336286-B528E5CD-4918-4250-8D28-FEA64E51E6BB Q27692588-564908CF-EE8F-4239-8244-E0E5ABFA00D8 Q28078386-9CF46D7E-BFD3-41D9-A4F1-13461D46A16A Q30462352-75AD883A-EF5E-43BF-B16E-C6F2C99EDAC4 Q30844779-141ADE79-A6E9-4F8F-A5D9-31DA04210B5C Q33552229-433BABDF-9E47-4076-A7D4-4B8516F4E0E8 Q34150566-0C10CE9A-DFCB-436E-B539-14151B860B93 Q34277031-CEBB28C9-B4E1-4BFD-8631-26F5D68E0481 Q34426209-B63DE195-D833-42EB-9CF1-65C705463DCA Q34428464-27B1D76D-A32E-4CF4-9AD7-81FC978D0DA2 Q34503360-321D851B-BDF3-4128-BB87-368845203036 Q35056906-30622680-6616-4CA1-AC68-A15C6411FAE1 Q35500693-A54D9DC4-04AF-4C8C-B573-8505B4ECDA88 Q35827798-0CC30F32-4AD7-467A-A0DF-0F6CF0070CE0 Q35850118-175FDDD7-1243-4ACD-AED9-F0FB08366373 Q36144664-C65BE239-43DD-4A17-AC3F-9330C260AE8F Q36357896-8A1479D0-F233-4418-881B-B7BEEC3ADC43 Q36735813-65097C59-6C48-4A02-983D-18C3D1A6F5A0 Q36893258-3E1A4566-88B5-495B-963C-31C3E6D7B6B0 Q37048738-25451C80-E065-4587-9172-CE60E737596A Q37115656-8B8253A5-AD28-447D-BFBB-427BD1502145 Q37225267-8840F89B-1F9C-4BD1-B502-949741023E4D Q37240968-9B0F9A2B-0DDC-4A1E-A9B1-68CEED036205 Q37398972-6B8A5F44-A370-4633-8749-FDBFD008AD2B Q37402473-F9D44DFF-5C97-4F3E-B78D-3CC7113D4354 Q37497840-6E865A79-0944-4003-80B6-E01922039A09 Q38040688-29A59E0C-2A8C-42AA-A0C3-EF963798E94C Q38191314-BE3AA220-A5CC-4C5C-81B8-27A9C9CFCB22 Q38258238-694CE4F9-CCDA-4F51-BF1A-E5066910EE4D Q39141728-F7491771-4479-41B6-9744-BFE7418C22AE Q39759995-32B93EF2-39CD-462A-B088-84050D1D54A0 Q41819549-B38D4DD5-0636-4083-85EC-5FC14A76669D Q42080105-FEFF8A28-EEC6-4D3C-96DA-B7B620A1B4B8 Q42557861-640F0322-B693-45F7-A809-3E8178F4E9EF Q44308542-04B19D78-0158-48A4-A37C-D85E98A67A51 Q44529978-13F9871F-4CAB-485C-BFEC-76FD7D28DC3D Q44970917-ECCBC6F5-0F39-4EA6-AF79-CD4C23AC0B2B Q45004611-A480C6C3-6C81-4219-A276-A8E7740EF0B4 Q46029902-F47F2BFD-4FE0-4276-9104-EFD14ECDD88B Q47278869-EBBFA256-E530-4EC3-BDB0-FED8120C3AE1

P2860

Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits

http://www.wikidata.org/entity/Q34543457

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Sildenafil and vardenafil but ...... ugh opening of mitochondrial K

@nl

Sildenafil and vardenafil but ...... following ischemia in rabbits

@en

type

label

Sildenafil and vardenafil but ...... ugh opening of mitochondrial K

@nl

Sildenafil and vardenafil but ...... following ischemia in rabbits

@en

prefLabel

Sildenafil and vardenafil but ...... ugh opening of mitochondrial K

@nl

Sildenafil and vardenafil but ...... following ischemia in rabbits

@en

P1433

Q34543457-D6B5D7C7-2EC6-4800-A832-037A6050B2F0

P1476

Q34543457-9725B847-B09A-4E73-9C7E-2C7E73183664

P2093

Q34543457-1AC4D4A5-30D0-44AC-8D51-65DD5A1F81BC

Q34543457-7A1F864F-9046-488B-BBF3-8B637DF8E14B

Q34543457-7BF7C57E-72A3-4081-B227-331AF11CB52E

Q34543457-96E81F82-F783-4F90-926C-F8B0ADDC430F

Q34543457-A1206450-034C-4A0B-90DE-F63FD0FE9592

Q34543457-D1EB11B8-945A-41E8-99FB-25DDBBE9713A

Q34543457-F56D7568-15CF-4CD0-BEA4-9A41030BD738

P2860

Q34543457-03931E9F-CD17-43A7-B9B0-868070A35F2E

Q34543457-0CF3B966-F8AF-4BE4-906C-2D1A6BEAE8A1

Q34543457-0D7B1B3F-C757-47D8-B172-E4C25B883362

Q34543457-0E995191-B79E-4027-BD32-7928C535BCE6

Q34543457-13A258D3-BC84-49C2-9252-7092D7041244

Q34543457-18C93EED-B359-48A9-922E-E00B0A58A7C3

Q34543457-26EC6F0E-24E3-49F8-9E83-E93978B11718

Q34543457-2C2D5262-2E1D-4404-A655-BDE449B9C8F1

Q34543457-367FC545-8428-4AC5-8CD9-1624FDA9F6F3

Q34543457-3A98447C-11CC-455D-8A41-B0012DF34089

P304

Q34543457-2D0B49ED-E5D6-4AB0-A4A8-99FEC6FDC194

P31

Q34543457-5AC818EE-61DC-4FD5-BC16-06D46E86F2F1

P356

Q34543457-AE331F05-F0CB-41BE-B75B-DB6C60D9F0A3

P433

Q34543457-B3E1B1FE-5661-4E29-AA9F-03A5185DE0CB

P478

Q34543457-E840C88D-2836-4F7D-8A1D-3B0D398D6707

P577

Q34543457-5BFC6FB8-1F12-4904-ABC5-6FA7566A8944

P5875

Q34543457-1E93D207-A7FD-4DE2-BFC0-5FB41045F9AE

P698

Q34543457-8B7477A8-7C5F-42EB-853F-128ECD4AF8FB

P921

Q34543457-DB8072C9-E4FC-479D-B95B-5D07FF42C185

P932

Q34543457-86F9C619-BDD7-428E-BB8B-EB3C845485C2

P356

J.YJMCC.2006.10.015

P1433

Journal of Molecular and Cellular Cardiology

P1476

Sildenafil and vardenafil but ...... following ischemia in rabbits

@en

P2093

Eric Chou

http://www.w3.org/2001/XMLSchema#string

Fadi N Salloum

http://www.w3.org/2001/XMLSchema#string

Kazu-ichi Yoshida

http://www.w3.org/2001/XMLSchema#string

Rakesh C Kukreja

http://www.w3.org/2001/XMLSchema#string

Ramzi A Ockaili

http://www.w3.org/2001/XMLSchema#string

Vladimir P Daoud

http://www.w3.org/2001/XMLSchema#string

Yuko Takenoshita

http://www.w3.org/2001/XMLSchema#string

P2860

Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection?

Comparison of milrinone versus nitroglycerin, alone and in combination, on grafted internal mammary artery flow after cardiopulmonary bypass: effects of alpha-adrenergic stimulation.

New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway.

The oxygen free radical system: from equations through membrane-protein interactions to cardiovascular injury and protection.

Therapy of ED: PDE-5 Inhibitors.

Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety.

Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction.

Phosphodiesterase 5 mechanisms and therapeutic applications.

Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors.

Guanylate cyclase: activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin.

P304

453-458

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YJMCC.2006.10.015

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6642868

http://www.w3.org/2001/XMLSchema#string

P698

17157308

http://www.w3.org/2001/XMLSchema#string

P921

P932

3031787

http://www.w3.org/2001/XMLSchema#string